Anifrolumab
D3461C00030
Phase 3 mab active
Quick answer
Anifrolumab for Systemic Lupus Erythematosus is a Phase 3 program (mab) at AstraZeneca with 1 ClinicalTrials.gov record(s).
Program details
- Company
- AstraZeneca
- Indication
- Systemic Lupus Erythematosus
- Phase
- Phase 3
- Modality
- mab
- Status
- active